Intelligenome

8955 Interchange Drive
Houston, TX 77054

United States

IGDx Inc (dba IntelliGenome) (Feb 13, 2024)

IGDX, Inc. develops diagnostic technology for the world’s serious health challenges and our vision is a diagnostic platform that transforms the lives of people impacted by infectious disease. We have developed and validated ultra-sensitive CRISPR-based detection of low abundance nucleic acid in small volume blood samples.
The first commercialization of our technology will be a first one Mycobacterium tuberculosis point-of-care detection test in blood sample, capable of delivering accurate and reliable results in hours. Our CRISPR-based platform will be ready to combat future infectious disease outbreaks ranging from non-Tuberculosis Mycobacterium (NTM) infections and HIV to global challenges posed by SARS and other emerging diseases.
Our team is in pursuit of a future where point-of-care disease diagnosis is not only accurate, affordable and rapid, but also an instrument of positive transformation, particularly in low-and-medium income countries.

Title